N. Hurst

Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist

J. Dingemanse, P. Kaufmann, B. Astruc, 2017, European Journal of Clinical Pharmacology.

Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension

J. Dingemanse, S. Bruderer, N. Hurst, 2017, Expert opinion on drug safety.

Lack of Pharmacokinetic Interactions Between Macitentan and a Combined Oral Contraceptive in Healthy Female Subjects

J. Dingemanse, P. Sidharta, N. Hurst, 2016, Journal of clinical pharmacology.

Multiple-Dose Up-Titration Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Selexipag, an Orally Available Selective Prostacyclin Receptor Agonist, in Healthy Subjects

J. Dingemanse, P. Kaufmann, S. Bruderer, 2014, Pharmacology.

Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension

J. Dingemanse, A. Krause, M. Machacek, 2017, CPT: pharmacometrics & systems pharmacology.

First-in-Humans Study of the Safety, Tolerability, and Pharmacokinetics of ACT-451840, a New Chemical Entity with Antimalarial Activity

R. de Kanter, J. Dingemanse, T. Pfeifer, 2014, Antimicrobial Agents and Chemotherapy.